HIV Protease Inhibitors

Antiviral Agents
Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir
Robert DiCenzo, Derick R. Peterson, Kim Cruttenden, Peter Mariuz, Naser L. Rezk, Jill Hochreiter, Harris Gelbard, Giovanni Schifitto
Susceptibility
Synergy of Human Immunodeficiency Virus Protease Inhibitors with Chloroquine against Plasmodium falciparum In Vitro and Plasmodium chabaudi In Vivo
Zhengxiang He, Li Qin, Lili Chen, Nanzheng Peng, Jianlan You, Xiaoping Chen
Susceptibility
Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum
U. Lek-Uthai, R. Suwanarusk, R. Ruengweerayut, T. S. Skinner-Adams, F. Nosten, D. L. Gardiner, P. Boonma, K. A. Piera, K. T. Andrews, B. MacHunter, J. S. McCarthy, N. M. Anstey, R. N. Price, B. Russell
Clinical Therapeutics
Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen
Nils von Hentig, Pavel Kaykhin, Christoph Stephan, Errol Babacan, Martin Stürmer, Schlomo Staszewski, Jörn Lötsch
Antiviral Agents
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors
Delphine Desbois, Bénédicte Roquebert, Gilles Peytavin, Florence Damond, Gilles Collin, Antoine Bénard, Pauline Campa, Sophie Matheron, Geneviève Chêne, Françoise Brun-Vézinet, Diane Descamps
and for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Antiviral Agents
Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742
Tatyana Dekhtyar, Teresa I. Ng, Liangjun Lu, Sherie Masse, David A. DeGoey, William J. Flosi, David J. Grampovnik, Larry L. Klein, Dale J. Kempf, Akhteruzzaman Molla
Antiviral Agents
Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens
Daniel Gonzalez de Requena, Stefano Bonora, Andrea Calcagno, Antonio D'Avolio, Marco Siccardi, Silvia Fontana, Maria Grazia Milia, Mauro Sciandra, Silvia Garazzino, Antonio Di Garbo, Lorena Baietto, Laura Trentini, Giovanni Di Perri
AUTHOR'S CORRECTION
Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients
Martin S. King, Richard Rode, Isabelle Cohen-Codar, Vincent Calvez, Anne-Geneviève Marcelin, George J. Hanna, Dale J. Kempf
Antiviral Agents
Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir
Sidonie Lambert-Niclot, Philippe Flandre, Ana Canestri, Gilles Peytavin, Christine Blanc, Rachid Agher, Cathia Soulié, Marc Wirden, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin
Antiviral Agents
In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1
Serge Dandache, Guy Sévigny, Jocelyn Yelle, Brent R. Stranix, Neil Parkin, Jonathan M. Schapiro, Mark A. Wainberg, Jinzi J. Wu

Main menu

User menu

Search

HIV Protease Inhibitors

Pages